Valink Therapeutics logo

Valink TherapeuticsDiscovering bispecific antibody drug-conjugates (BsADC) against cancer

Valink Therapeutics develops next generation antibody-based therapeutics. We identify novel mechanism of action from known targets by incorporating multiple antibody modifications at once, rapidly and scalable generating complex drug candidates (bi-/multispecificity, multivalency and drug-conjugation in a single discovery process). Our research focus is on solid tumours poorly addressed by immunotherapy.

2021-03-01
Active
Early
W21
12
Healthcare
United KingdomEurope
Valink Therapeutics screenshot